APOA4

Chr 11q23.3

apolipoprotein A4

MANE:: ENST00000357780.5

OMIM: 107690 ↗NCBI: 337 ↗Ensembl ↗

Annotations refreshed 9 hours ago.

Predicted protein structure

AlphaFold predicted structure

APOA4 · P06727

v62025-08-01

Predicted Aligned Error matrix for APOA4 — diagonal shows residue index, colour shows pairwise prediction confidence (lower is better) — Predicted Aligned Error

Mean pLDDT

80.8/ 100

Confident

396 residues

Confidence breakdown

Very high(≥ 90)43%
Confident(70–90)32%
Low(50–70)20%
Very low(< 50)5%

Open interactive 3D viewer

AlphaFold (Jumper et al., 2021) · CC BY 4.0

Clinical relevance (Genomics England PanelApp)

Moderate Evidence (Amber)

Hereditary systemic amyloidosis
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown
Tubulointerstitial kidney disease
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted

Disease associations (Open Targets)

tubulointerstitial kidney disease, autosomal dominant, 2
0.48
AL amyloidosis
0.46
diabetes mellitus
0.35
familial hyperlipidemia
0.33
type 2 diabetes mellitus
0.32
Hypercholesterolemia
0.20
placental retention
0.18
hypertriglyceridemia
0.18
response to statin
0.17
metabolic syndrome
0.17

Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.

Protein function (UniProt)

Apolipoprotein A-IV

May have a role in chylomicrons and VLDL secretion and catabolism. Required for efficient activation of lipoprotein lipase by ApoC-II; potent activator of LCAT. Apoa-IV is a major component of HDL and chylomicrons